Date:3/16/2010

Ms. Steiger served as the Managing Partner at Topridge Associates LLC, a privately held consultant agency she founded. She also serves on the corporate board of Aviva USA and was a member of the Executive Management Committee at Neuberger Berman until 2004.

Joseph L. Turner currently sits on the boards of QLT Inc, ApopLogic Pharmaceuticals, Inc., Kythera Biopharmaceuticals, Inc., Sequel Pharmaceuticals, Inc. and Swarthmore College. He has served as Chief Financial Officer of Myogen, Inc. and Centaur Pharmaceuticals.

Citigroup is acting as exclusive financial advisor to Astellas and Morrison & Foerster LLP is acting as legal counsel.

Additional Information

Further details related to this proposal can be found on www.oncologyleader.com

'/>"/>

SOURCE Astellas Pharma Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
2. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
3. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
4. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
5. CardioGenics Announces Lock-Up Agreement with Dr. Yahia Gawad
6. Bionovo Announces 2009 Highlights and Year-End Financial Results
7. CT Corsearch Announces Trademark Search Capabilities for the U.S. Pharmaceutical Market
8. Poniard Pharmaceuticals Announces $6.3 Million Financing
9. Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
10. HEI, Inc. Announces Qualification to MIL-P-50884E
11. Otix Global, Inc. Announces Reverse Stock Split